{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:32:30Z","timestamp":1787628750997,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejmech.2024.116823","type":"journal-article","created":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:58:27Z","timestamp":1725152307000},"page":"116823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Improved N-phenylpyrrolamide inhibitors of DNA gyrase as antibacterial agents for high-priority bacterial strains"],"prefix":"10.1016","volume":"278","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1905-0158","authenticated-orcid":false,"given":"Nace","family":"Zidar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Onali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Per\u0161olja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Benedetto Tiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaka","family":"Dernov\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017diga","family":"Skok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Durcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej Emanuel","family":"Cotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Hrast Rambaher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina D.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4ivi","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidija","family":"Senerovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milija","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra \u00c9va","family":"Szili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rton Simon","family":"Czikkely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"P\u00e1l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamarija","family":"Zega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucija","family":"Peterlin Ma\u0161i\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janez","family":"Ila\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tihomir","family":"Toma\u0161i\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danijel","family":"Kikelj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10325","key":"10.1016\/j.ejmech.2024.116823_bib1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejmech.2024.116823_bib2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41570-021-00313-1","article-title":"Towards the sustainable discovery and development of new antibiotics","volume":"5","author":"Miethke","year":"2021","journal-title":"Nat. Rev. Chem"},{"issue":"3","key":"10.1016\/j.ejmech.2024.116823_bib3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00253-011-3557-z","article-title":"Exploiting bacterial DNA gyrase as a drug target: current state and perspectives","volume":"92","author":"Collin","year":"2011","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116823_bib4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/1568026613666131113153251","article-title":"Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases","volume":"14","author":"Tomasic","year":"2014","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116823_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112326","article-title":"Recent advances in DNA gyrase-targeted antimicrobial agents","volume":"199","author":"Dighe","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116823_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000819","article-title":"Rational design of balanced dual-targeting antibiotics with limited resistance","volume":"18","author":"Nyerges","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejmech.2024.116823_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bioorg.2015.07.004","article-title":"Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: a review","volume":"62","author":"Azam","year":"2015","journal-title":"Bioorg. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116823_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01208-21","article-title":"First-in-Human evaluation of the safety, tolerability, and pharmacokinetics of SPR720, a novel oral bacterial DNA gyrase (GyrB) inhibitor for mycobacterial infections","volume":"65","author":"Talley","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116823_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02537-17","article-title":"Phase 1 study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DS-2969b, a novel GyrB inhibitor, in healthy subjects","volume":"62","author":"Vandell","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116823_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084409","article-title":"Tricyclic GyrB\/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents","volume":"8","author":"Tari","year":"2013","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.ejmech.2024.116823_bib11","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1021\/jm500462x","article-title":"Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099)","volume":"57","author":"Basarab","year":"2014","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116823_bib12","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1016\/j.apsb.2023.08.030","article-title":"Discovery and druggability evaluation of pyrrolamide-type GyrB\/ParE inhibitor against drug-resistant bacterial infection","volume":"13","author":"Zhao","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"14","key":"10.1016\/j.ejmech.2024.116823_bib13","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1021\/acs.jmedchem.5b00489","article-title":"Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as novel DNA gyrase inhibitors targeting the ATP-binding site","volume":"58","author":"Toma\u0161i\u010d","year":"2015","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.ejmech.2024.116823_bib14","doi-asserted-by":"crossref","first-page":"8941","DOI":"10.1021\/acs.jmedchem.6b00864","article-title":"Discovery of benzothiazole scaffold-based DNA gyrase B inhibitors","volume":"59","author":"Gjorgjieva","year":"2016","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116823_bib15","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1021\/acs.jmedchem.2c01597","article-title":"Discovery and hit-to-lead optimization of benzothiazole scaffold- based DNA gyrase inhibitors with potent activity against acinetobacter baumannii and Pseudomonas aeruginosa","volume":"66","author":"Cotman","year":"2023","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116823_bib16","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1021\/acs.jmedchem.2c01905","article-title":"New dual inhibitors of bacterial topoisomerases with broad-spectrum antibacterial activity and in vivo efficacy against vancomycin-intermediate Staphylococcus aureus","volume":"66","author":"Durcik","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116823_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113200","article-title":"New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens","volume":"213","author":"Durcik","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"27","key":"10.1016\/j.ejmech.2024.116823_bib18","doi-asserted-by":"crossref","first-page":"24387","DOI":"10.1021\/acsomega.3c01930","article-title":"Exploring the 5-substituted 2-aminobenzothiazole-based DNA gyrase B inhibitors active against ESKAPE pathogens","volume":"8","author":"Sterle","year":"2023","journal-title":"ACS Omega"},{"issue":"15","key":"10.1016\/j.ejmech.2024.116823_bib19","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1021\/acs.jmedchem.5b00775","article-title":"N-Phenyl-4,5-dibromopyrrolamides and N-phenylindolamides as ATP competitive DNA gyrase B inhibitors: design, synthesis, and evaluation","volume":"58","author":"Zidar","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116823_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejmech.2018.05.011","article-title":"New N-phenylpyrrolamide DNA gyrase B inhibitors: optimization of efficacy and antibacterial activity","volume":"154","author":"Durcik","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116823_bib21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/cmdc.201700549","article-title":"Synthesis and evaluation of N-phenylpyrrolamides as DNA gyrase B inhibitors","volume":"13","author":"Durcik","year":"2018","journal-title":"ChemMedChem"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116823_bib22","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1039\/C9MD00224C","article-title":"New N-phenyl-4,5-dibromopyrrolamides as DNA gyrase B inhibitors","volume":"10","author":"Zidar","year":"2019","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2024.116823_bib23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejmech.2016.03.079","article-title":"New N-phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATPase inhibitors of DNA gyrase","volume":"117","author":"Zidar","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116823_bib24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ejmech.2019.02.004","article-title":"An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors","volume":"167","author":"Tiz","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116823_bib25","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1021\/acs.jmedchem.2c01905","article-title":"New dual inhibitors of bacterial topoisomerases with broad-spectrum antibacterial activity and in vivo efficacy against vancomycin-intermediate Staphylococcus aureus","volume":"66","author":"Durcik","year":"2023","journal-title":"J. Med. Chem."},{"issue":"7654","key":"10.1016\/j.ejmech.2024.116823_bib26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nature22308","article-title":"Predictive compound accumulation rules yield a broad-spectrum antibiotic","volume":"545","author":"Richter","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116823_bib27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nyas.13598","article-title":"The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics","volume":"1435","author":"Richter","year":"2019","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116823_bib28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/17460441.2018.1455660","article-title":"Overcoming problems of poor drug penetration into bacteria: challenges and strategies for medicinal chemists","volume":"13","author":"Benedetto Tiz","year":"2018","journal-title":"Expet Opin. Drug Discov."},{"issue":"17","key":"10.1016\/j.ejmech.2024.116823_bib29","doi-asserted-by":"crossref","first-page":"10145","DOI":"10.1021\/acsomega.0c00865","article-title":"Lead identification of 8-(Methylamino)-2-oxo-1,2-dihydroquinoline derivatives as DNA gyrase inhibitors: hit-to-lead generation involving thermodynamic evaluation","volume":"5","author":"Ushiyama","year":"2020","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116823_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1021\/id500013t","article-title":"A new-class antibacterial-almost. Lessons in drug discovery and development: a critical analysis of more than 50 Years of effort toward ATPase inhibitors of DNA gyrase and topoisomerase IV","volume":"1","author":"Bisacchi","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2024.116823_bib31","unstructured":"MarvinSketch 23.16, ChemAxon Ltd., https:\/\/chemaxon.com\/marvin."},{"issue":"39","key":"10.1016\/j.ejmech.2024.116823_bib32","doi-asserted-by":"crossref","first-page":"9338","DOI":"10.1039\/C6OB01644H","article-title":"A one-pot synthesis of tetrazolones from acid chlorides: understanding functional group compatibility, and application to the late-stage functionalization of marketed drugs","volume":"14","author":"Duncton","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2024.116823_bib33","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Ninth Edition. CLSI Document M07-A9","year":"2012"},{"key":"10.1016\/j.ejmech.2024.116823_bib34","unstructured":"PyMOL, Delano Scientific LLC, San Francisco, CA, http:\/\/pymol.sourceforge.net."},{"key":"10.1016\/j.ejmech.2024.116823_bib35","unstructured":"DataWarrior 5.0.0, openmolecules.org, https:\/\/openmolecules.org\/datawarrior."},{"key":"10.1016\/j.ejmech.2024.116823_bib36","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejmech.2012.06.043","article-title":"Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design","volume":"57","author":"Di","year":"2012","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116823_bib37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2478\/acph-2019-0024","article-title":"Metabolic stability and its role in the discovery of new chemical entities","volume":"69","author":"Sloczynska","year":"2019","journal-title":"Acta Pharm."},{"key":"10.1016\/j.ejmech.2024.116823_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104049","article-title":"Discovery of new ATP-competitive inhibitors of human DNA topoisomerase II\u03b1 through screening of bacterial topoisomerase inhibitors","volume":"102","author":"Skok","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116823_bib39","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Ninth Edition. CLSI Document M07-A9","year":"2012"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116823_bib40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/infdis\/135.2.217","article-title":"Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time","volume":"135","author":"McDonald","year":"1977","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116823_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097539","article-title":"Hp1404, a new antimicrobial peptide from the scorpion Heterometrus petersii","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ejmech.2024.116823_bib42","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1039\/D3MD00134B","article-title":"Design, synthesis, and mechanistic study of 2-piperazineone-bearing peptidomimetics as novel HIV capsid modulators","volume":"14","author":"Zhang","year":"2023","journal-title":"RSC Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424007049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424007049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T09:52:35Z","timestamp":1726221155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424007049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":42,"alternative-id":["S0223523424007049"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116823","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved N-phenylpyrrolamide inhibitors of DNA gyrase as antibacterial agents for high-priority bacterial strains","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116823","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116823"}}